IPO
Key Metrics
Total funding
IPO gross proceeds ~$155.5M (incl. private placement)
As of Jul 27, 2026Scribe Therapeutics
Company Snapshot
Scribe Therapeutics is a Biotech company, based in Alameda, California, USA, founded 2018 by Benjamin Oakes, Jennifer Doudna, Brett T. Staahl. Market cap $542.77M (As of Sep 4, 2026, stockanalysis.com). Total funding IPO gross proceeds ~$155.5M (incl. private placement) (As of Jul 27, 2026).
Recent changes
- Sep 4, 2026Sep 4, 2026First reported market cap: $542.77M stockanalysis.com
- Jul 27, 2026Jul 27, 2026First reported total funding: IPO gross proceeds ~$155.5M (incl. private placement) Scribe Therapeutics
- Jul 24, 2026Jul 24, 2026IPO $155.5M (incl. private placement) Scribe Therapeutics
- Jul 24, 2026Jul 24, 2026Scribe Therapeutics Prices Upsized IPO With Sanofi Backing Pulse story
- Jul 23, 2026Jul 23, 2026Scribe Therapeutics Soars In Rare Gene-Editing IPO Pulse story
Earlier changes (6)
- Jul 10, 2026Jul 10, 2026Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO Pulse story
- Jul 2, 2026Jul 2, 2026Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO Pulse story
- Jul 2, 2026Jul 2, 2026Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite Pulse story
- Oct 6, 2020Oct 6, 2020Raised $20M Series A TechCrunch
- Oct 6, 2020Oct 6, 2020New investor: Andreessen Horowitz TechCrunch
- 20172017IPO $150 millionRumored SEC EDGAR
Funding History
3 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 24, 2026 | IPO | $155.5M (incl. private placement) | — | Scribe Therapeutics | |
| Oct 6, 2020 | Series A | $20M | — | outlined = lead | TechCrunch |
| Jan 1, 2017 | ipoRumored | $150 million | — | Pulse story |
Investors
Latest Pulse
- Jul 24, 2026Scribe Therapeutics Prices Upsized IPO With Sanofi BackingGene-editing biotech Scribe Therapeutics priced an upsized IPO at $15 per share, raising $128.7 million with Sanofi as a strategic anchor investor, the first gene-editing IPO in over two years.→
- Jul 23, 2026Scribe Therapeutics Soars In Rare Gene-Editing IPOScribe Therapeutics priced an upsized $128.7 million IPO and surged in its Nasdaq debut, a rare early-stage listing for a gene-editing biotech in a market that has favored de-risked, later-stage companies.→
- Jul 10, 2026Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPOScribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.→
- Jul 2, 2026Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPOScribe Therapeutics filed its S-1 with the SEC on July 2, seeking to list on the Nasdaq Global Market under the ticker 'SCTX.' The clinical-stage biotech, co-founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna, has raised roughly $150 million in equity financing since 2017 and is advancing STX-1150 -- an epigenetic-silencing CRISPR candidate for cardiovascular disease -- through an Australian first-in-human trial, while disclosing only $49.7 million in cash and marketable securities against a $175.1 million accumulated deficit.→
- Jul 2, 2026Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech AppetiteScribe Therapeutics filed to raise up to $75 million in a Nasdaq IPO, becoming an early test of public-market appetite for Phase 1 biotechs -- its lead candidate, a CRISPR-based epigenetic therapy targeting PCSK9 to lower LDL cholesterol, is already in a.→
Coverage Timeline
newest first- Jul 24, 2026IPOScribe Therapeutics Prices Upsized IPO With Sanofi Backing$128.7M Raised→
- Jul 23, 2026IPOScribe Therapeutics Soars In Rare Gene-Editing IPO$128.7M IPO→
- Jul 10, 2026IPODoudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO$180M+ partnership payments→
- Jul 2, 2026IPOScribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPOS-1 filed→
- Jul 2, 2026IPOScribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech AppetiteUp to $75M IPO→
All Coverage
IPO$128.7M Raised
Scribe Therapeutics Prices Upsized IPO With Sanofi Backing
Gene-editing biotech Scribe Therapeutics priced an upsized IPO at $15 per share, raising $128.7 million with Sanofi as a strategic anchor investor, the first gene-editing IPO in over two years.
IPO
Scribe Therapeutics Soars In Rare Gene-Editing IPO
IPO$128.7M IPO
Scribe Therapeutics Soars In Rare Gene-Editing IPO
Scribe Therapeutics priced an upsized $128.7 million IPO and surged in its Nasdaq debut, a rare early-stage listing for a gene-editing biotech in a market that has favored de-risked, later-stage companies.
IPO
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
IPO$180M+ partnership payments
Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.
IPO
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
IPOS-1 filed
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
Scribe Therapeutics filed its S-1 with the SEC on July 2, seeking to list on the Nasdaq Global Market under the ticker 'SCTX.' The clinical-stage biotech, co-founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna, has raised roughly $150 million in equity financing since 2017 and is advancing STX-1150 -- an epigenetic-silencing CRISPR candidate for cardiovascular disease -- through an Australian first-in-human trial, while disclosing only $49.7 million in cash and marketable securities against a $175.1 million accumulated deficit.
IPO
Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
IPOUp to $75M IPO
Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech Appetite
Scribe Therapeutics filed to raise up to $75 million in a Nasdaq IPO, becoming an early test of public-market appetite for Phase 1 biotechs -- its lead candidate, a CRISPR-based epigenetic therapy targeting PCSK9 to lower LDL cholesterol, is already in a.
Related Companies
Shared investors
Sources & methodologyshow
Where these figures come from
- Scribe Therapeuticsprimary source2 facts
- SEC EDGARprimary source1 fact
- TechCrunchmajor outlet1 fact
- stockanalysis.comresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.